It’s that time of year again when Big Pharma companies publicly release the total compensation for their CEOs and top executives from the year before.
Over the coming weeks, publicly-traded pharma and biotech companies will outline how much their leadership teams received in base pay and salaries during 2023.
The issue of executive pay is one that is closely watched — and occasionally criticized — across the industry in light of debates surrounding income inequality and the ratio of CEO salaries to that of median employees.
Check out the list below of total executive compensation for pharma companies, which will be updated throughout the spring.
AstraZeneca
AstraZeneca CEO Pascal Soriot received a total compensation package of £16.9 million in 2023, up from £15.3 million in 2022.
In the company’s annual report issued earlier this week, the British pharma giant indicated that Soriot is eligible to receive up to £18.6 million this year depending on the company’s financial performance.
During its most recent quarter, the drugmaker recorded total revenue of just over $12 billion, with its reported earnings per share (EPS) rising 5% at constant exchange rates (CER) to $0.62, while its core EPS increased 7% to $1.45.
For the full year, AstraZeneca’s total revenues rose 6% to $45.8 billion, supported by 4% product sales revenue growth. The company’s reported EPS increased 96% year-over-year to $3.84 and its core EPS rose 15% to $7.26.
However, that wasn’t enough to impress Wall Street analysts, as the quarterly core EPS was below analyst expectations of $1.48 and the revenue figure barely exceeded expectations of $12.01 billion.
Entradas
No hay comentarios:
Publicar un comentario